false
0001137883
0001137883
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2026
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
001-36641 |
|
20-7273918 |
(State or other jurisdiction of
incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
| 1325 Avenue of Americas, 28th Floor |
|
| New York, NY |
10019 |
| (Address of principal executive offices) |
(Zip Code) |
(201) 488-0460
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| |
|
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 16, 2026,
Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The
full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in
this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | |
Description |
| 99.1 | |
Press Release issued
by Brainstorm Cell Therapeutics Inc. on November 16, 2026. |
| 104 | |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
BRAINSTORM CELL THERAPEUTICS INC. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Chaim Lebovits |
| |
|
Chaim Lebovits |
| |
|
President and Chief Executive Officer |
Exhibit 99.1
BrainStorm Cell Therapeutics Announces Third
Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, November 16, 2026 /PRNewswire/ --
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today
announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“ALS remains a devastating disease with
a critical unmet medical need, and patients urgently need new therapeutic options,” said Chaim Lebovits, President and Chief Executive
Officer of BrainStorm. “We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study
of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we
strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators,
potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead
the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior
FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase,
and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community.”
Recent Highlights
Clinical, Scientific, and Regulatory Progress
| · | Advancing Phase 3b ENDURANCE
Readiness & Constructive Regulatory Backdrop. BrainStorm continues to execute on operational, clinical, and manufacturing activities
to support the initiation of the Phase 3b ENDURANCE study of NurOwn® (MSC-NTF cells) in earlier-stage ALS patients under
its FDA-agreed Special Protocol Assessment (SPA). The Company also notes the FDA’s October 2026 launch of its Rare Disease Framework
Initiative, aimed at establishing a more holistic, fit-for-purpose regulatory framework for rare diseases with severe unmet medical needs. |
| · | Peer-Reviewed
Publication on NurOwn®-Derived Extracellular Vesicles (ExMN). BrainStorm’s
R&D team published “Beneficial effects of small extracellular vesicles derived
from MSC-NTF (NurOwn®) cells on lung inflammation and fibrosis” in Stem
Cell Research & Therapy, a Q1-ranked journal (DOI: 10.1186/s13287-026-05303-y).
The study demonstrated reduced lung inflammation and fibrosis, improved oxygenation, and
protection against subsequent lung injury following inhaled pretreatment in preclinical models,
supporting the therapeutic and preventive potential of NurOwn®-Derived Extracellular
Vesicles (ExMN). |
Corporate and Leadership
| · | Appointed Professor Peter
J. Pitts as Executive Chairman. On July 28, 2026, BrainStorm announced the appointment of Professor Peter J. Pitts, a former FDA Associate
Commissioner and co-founder of the Center for Medicine in the Public Interest, as Executive Chairman and Chief Strategic Regulatory and
Policy Officer. Professor Pitts, who joined the Board in May 2026, leads the Company’s daily operations, partnerships, investor
engagement, and regulatory strategy, focused primarily on advancing the Phase 3b ENDURANCE trial. Professor Jacob Frenkel, a member of
BrainStorm’s leadership team since 2007 and Board Chairman since 2020, transitioned to Senior Advisor. |
Industry and Investor Engagement
| · | Participated in DUPHAT 2026
in Dubai. In August 2026, CEO Chaim Lebovits and Executive Chairman Professor Peter J. Pitts participated in the 31st Dubai International
Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) at the Dubai World Trade Centre. Professor Pitts delivered keynote
addresses and moderated panel sessions on regulatory science harmonization and translational collaboration, while BrainStorm’s leadership
met with regional health regulators, commercial distribution partners, and international investment groups regarding the strategic positioning
of NurOwn® and the planned Phase 3b ENDURANCE trial. |
Financial Results for the Third Quarter Ended September 30, 2026
| · | Cash, cash equivalents, and restricted cash were approximately $0.35 million as of September 30, 2026,
compared to approximately $0.24 million as of September 30, 2025. |
| · | Research and development expenditures, net, for the third quarter of 2026 were approximately $0.5 million,
compared to approximately $0.9 million for the third quarter of 2025. |
| · | General and administrative expenses for the third quarter of 2026 were approximately $1.09 million, compared
to approximately $1.15 million for the third quarter of 2025. |
| · | Net loss for the third quarter of 2026 was approximately $1.7 million, compared to a net loss of approximately
$2.1 million for the third quarter of 2025. |
| · | Net loss per share for the third quarters of 2026 and 2025 was $(0.14) and $(0.19), respectively. |
U.S. dollars in thousands
(Except share and per share amounts)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| | |
Unaudited | | |
Audited | |
| | |
U.S. $ in thousands | |
| ASSETS | |
| | | |
| | |
| | |
| | | |
| | |
| Current Assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 163 | | |
$ | 29 | |
| Other accounts receivable | |
| 189 | | |
| 86 | |
| Prepaid expenses and other current assets | |
| 101 | | |
| 192 | |
| Total current assets | |
$ | 453 | | |
$ | 307 | |
| | |
| | | |
| | |
| Long-Term Assets: | |
| | | |
| | |
| Prepaid expenses and other long-term assets | |
$ | 26 | | |
$ | 25 | |
| Restricted Cash | |
| 185 | | |
| 247 | |
| Right of use asset | |
| 53 | | |
| 208 | |
| Property and equipment, net | |
| 123 | | |
| 235 | |
| Total Long-Term Assets | |
$ | 387 | | |
$ | 715 | |
| | |
| | | |
| | |
| Total assets | |
$ | 840 | | |
$ | 1,022 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
| | |
| | | |
| | |
| Current Liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 7,473 | | |
$ | 7,067 | |
| Accrued expenses | |
| 464 | | |
| 396 | |
| Short-term loans | |
| 1,875 | | |
| 967 | |
| Operating lease liability | |
| 56 | | |
| 208 | |
| Employees related liability | |
| 3,304 | | |
| 2,369 | |
| Total current liabilities | |
$ | 13,172 | | |
$ | 11,007 | |
| | |
| | | |
| | |
| Total liabilities | |
$ | 13,172 | | |
$ | 11,007 | |
| | |
| | | |
| | |
| Stockholders’ Deficit: | |
| | | |
| | |
| Stock capital: | |
| 16 | | |
| 16 | |
| Common stock $0.00005 par value; 250,000,000 shares authorized at September 30, 2026 and December 31, 2025; 14,259,377 and 11,034,775 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | |
| | | |
| | |
| Additional paid-in-capital | |
| 232,426 | | |
| 227,058 | |
| Treasury stock | |
| (116 | ) | |
| (116 | ) |
| Accumulated deficit | |
| (244,658 | ) | |
| (236,943 | ) |
| Total stockholders’ deficit | |
$ | (12,332 | ) | |
$ | (9,985 | ) |
| | |
| | | |
| | |
| Total liabilities and stockholders’ deficit | |
$ | 840 | | |
$ | 1,022 | |
The accompanying notes are an integral part of the
consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF
COMPREHENSIVE LOSS (UNAUDITED)
U.S. dollars in thousands
(Except share and per share amounts)
| | |
Nine months ended | | |
Three months ended | |
| | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Unaudited | | |
Unaudited | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development, net | |
$ | 2,248 | | |
$ | 3,323 | | |
$ | 523 | | |
$ | 899 | |
| General and administrative | |
| 5,026 | | |
| 4,386 | | |
| 1,092 | | |
| 1,148 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating loss | |
| (7,274 | ) | |
| (7,709 | ) | |
| (1,615 | ) | |
| (2,047 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Financial income (expense), net | |
| (441 | ) | |
| (343 | ) | |
| (118 | ) | |
| (59 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Gain (loss) on change in fair value of Warrants liability | |
| - | | |
| 179 | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (7,715 | ) | |
$ | (7,873 | ) | |
$ | (1,733 | ) | |
$ | (2,106 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Basic and diluted net loss per share from continuing operations | |
$ | (0.68 | ) | |
$ | (0.91 | ) | |
$ | (0.14 | ) | |
$ | (0.19 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share | |
| 11,354,405 | | |
| 8,673,908 | | |
| 11,983,241 | | |
| 11,008,047 | |
About NurOwn®
The NurOwn® technology platform (autologous
MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative
disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated
ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels
of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines
directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI)
is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary
NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed
to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm’s lead investigational
therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is
set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights
into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal
time points, and a comprehensive analysis of the “Floor Effect,” a critical challenge in measuring clinical outcomes in advanced
ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2
open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National
MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and
nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent
covering its exosome technology, further strengthening BrainStorm’s growing IP portfolio in this emerging area of regenerative
medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking
statements” that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food
and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment
of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of
historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release
may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will”, “would,” or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BrainStorm’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation,
management’s ability to successfully achieve its goals, BrainStorm’s ability to raise additional capital, BrainStorm’s
ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm’s future interactions
with the FDA will have productive outcomes, and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place
undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based
on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation
to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations
or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking
statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Media:
Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911
uri@brainstorm-cell.com